THERAPY DOSSIER · th-3f5d59628610

Citrullus colocynthis ethanolic fruit extract

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02155361 ↗PHASE1/PHASE2completed

Evaluation of Topical Citrullus Colocynthis Fruit Oil Efficacy in Treatment of Painful Peripheral Diabetic Neuropathy

Diabetic Neuropathies

Enrolment: 70 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29236674 ↗2017Reported benefit

Citrullus colocynthis Linn. Fruit extract ameliorates cisplatin-induced hepato-renal toxicity in rats.

RatChemical/toxinWistar (albino)Malen = 30 rats in 5 groups of 6Oral (p.o.)100, 200 or 400 mg/kgPretreatment for 10 days with cisplatin given on day 7, one hour after extract…

Model: Cisplatin (7.5 mg/kg intraperitoneal) induced hepato-renal toxicity

Citrullus colocynthis at 100 to 400 mg/kg attenuated cisplatin-induced rises in ALT, ALP, creatinine and blood urea nitrogen, normalised haematological changes, reduced malondialdehyde and nitrite, restored glutathione, catalase and superoxide dismutase, and preserved liver and kidney histoarchitec…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…